Laura del Puerto Nevado-rekin lankidetzan egindako argitalpenak (15)

2024

  1. Correction to: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells (British Journal of Cancer, (2024), 130, 8, (1402-1413), 10.1038/s41416-024-02649-z)

    British Journal of Cancer

  2. Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells

    British Journal of Cancer, Vol. 130, Núm. 8, pp. 1402-1413

  3. POLQ immunostaining behaves as a prognostic factor for pancreatic carcinoma

    Frontiers in Oncology, Vol. 14

  4. Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest

    Molecular Oncology, Vol. 18, Núm. 9, pp. 2212-2233

2021

  1. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer

    Biomedicine and Pharmacotherapy, Vol. 144

2020

  1. Strong Antitumor Activity of Bevacizumab and Aflibercept in Neuroendocrine Carcinomas: In-Depth Preclinical Study

    Neuroendocrinology, Vol. 110, Núm. 1-2, pp. 50-62

  2. TRIM72 Immunohistochemical Expression Can Predict Relapse in Colorectal Carcinoma

    Pathology and Oncology Research, Vol. 26, Núm. 2, pp. 861-865

  3. Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas

    Neuroendocrinology, Vol. 111, Núm. 1-2, pp. 146-157

2018

  1. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

    BMC Cancer, Vol. 18, Núm. 1

2017

  1. CPEB4 immunohistochemical expression is associated to prognosis in stage IV colorectal carcinoma

    Pathology Research and Practice, Vol. 213, Núm. 6, pp. 639-642

2016

  1. Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy

    Pathology Research and Practice, Vol. 212, Núm. 12, pp. 1133-1137

  2. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer

    Journal of Cellular and Molecular Medicine, Vol. 20, Núm. 9, pp. 1729-1736

  3. Predictive value of vrk 1 and 2 for rectal adenocarcinoma response to neoadjuvant chemoradiation therapy: A retrospective observational cohort study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Identification of Poor-outcome Biliopancreatic Carcinoma Patients with Two-marker Signature Based on ATF6α and p-p38 "sTARD Compliant"

    Medicine (United States), Vol. 94, Núm. 45, pp. e1972

2014

  1. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1